Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing portal pressure. Whether weight reduction can be safely achieved through lifestyle (LS) changes (diet and exercise) in overweight/obese patients with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown. This prospective, multicentric, uncontrolled pilot study enrolled patients with compensated cirrhosis, portal hypertension (hepatic venous pressure gradient [HVPG] 6 mm Hg), and body mass index (BMI) 26 kg/m 2 in an intensive 16-week LS intervention program (personalized hypocaloric normoproteic diet and 60 min/wk of supervised physical activity). We measured HVPG, body weight (BW) and composition, adipokines, health-related quality of life, and safety data before and after the intervention. Changes in HVPG and BW were predefined as clinically relevant if 10% and 5%, respectively. Safety and BW were reassessed after 6 months. 60 patients were included and 50 completed the study (56 6 8 years old; 62% male; nonalcoholic steatohepatitis etiology 24%; BMI 33.3 6 3.2 kg/m 2 ; Child A 92%; HVPG 10 mm Hg, 72%). LS intervention significantly decreased BW (average, -5.0 6 4.0 kg; P < 0.0001), by 5% in 52% and 10% in 16%. HVPG also significantly decreased (from 13.9 6 5.6 to 12.3 6 5.2 mm Hg; P < 0.0001), by 10% in 42% and 20% in 24%. A 10% BW loss was associated with a greater decrease in HVPG (-23 O besity and obesity-associated conditions are growing health problems worldwide. In recent prospective studies, over 70% of patients with compensated cirrhosis were either overweight or obese, (1, 2) similarly to the general population.
O besity and obesity-associated conditions are growing health problems worldwide. In recent prospective studies, over 70% of patients with compensated cirrhosis were either overweight or obese, (1, 2) similarly to the general population. (1, 2) Besides being a cause of chronic liver disease per se, obesity worsens the prognosis of patients with compensated cirrhosis induced by other causes, (1, 2) and the risk of first clinical decompensation of cirrhosis is approximately 3 times higher in obese patients as compared to normal weight ones. (1, 2) The mechanisms explaining this clinical association have not been Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BIA, bioelectrical impedance analysis; BMI, body mass index; BW, body weight; CSPH, clinically significant portal hypertension; EV, esophageal varices; HCC, hepatocellular carcinoma; HGF, hepatocyte growth factor; HOMA, homeostasis model assessment; HVPG, hepatic venous pressure gradient; IL, interleukin; LS, lifestyle; MCP-1, monocyte chemoattractant protein 1; MELD, Model for End-Stage Liver Disease; METs, metabolic equivalents of tasks; NAFLD, nonalcoholic fatty liver disease; NGF, nerve growth factor; NASH, nonalcoholic steatohepatitis; NS, not significant; NSBBs, nonselective beta-blockers; QUICKI, quantitative insulin sensitivity check index; TNFa, tumor necrosis factor alpha.
clarified yet, but appears to involve a progressive increase in portal pressure. (1) Given that portal hypertension constitutes the pathophysiological basis of most complications of cirrhosis, (3) therapeutic measures for patients with cirrhosis should be aimed at reducing portal pressure. In particular, nonpharmacological strategies to improve portal hypertension would be highly desirable. (4) Weight loss 5%-7% obtained by combining hypocaloric diet and exercise is an effective treatment for obesity-related chronic liver disease (nonalcoholic fatty liver disease; NAFLD) (5, 6) ; furthermore, such a relatively modest weight loss is sufficient to determine clinically relevant improvements in other clinical scenarios, such as a reduction of cardiovascular risk in overweight and obese patients with type 2 diabetes. (7) Mechanisms involved include improvement in insulin resistance and reduction in proinflammatory, -fibrogenic, and -angiogenic adipokines/cytokines. Some of these cytokines, such as leptin, have been suggested to modulate portal hypertension in cirrhosis; we have recently shown that leptin receptor blockade decreased hepatic vascular resistance and portal pressure in experimental cirrhosis, (8) which supports the view that excessive leptin release might exacerbate portal hypertension in obese patients with cirrhosis.
However, the safety of weight loss in patients with cirrhosis has not been fully established yet, and there is concern regarding possible deleterious effects on liver function mediated by worsening of sarcopenia. (9) Given the above-mentioned evidence, we hypothesized that an intensive lifestyle (LS) intervention consisting in a personalized and monitorized hypocaloric diet and supervised moderate physical exercise would result in improvement in portal hypertension in patients with compensated cirrhosis and overweight or obesity; this effect would be mediated by a decrease in intrahepatic vascular resistance. Furthermore, intensive LS intervention would be associated with a modest body weight (BW) loss without adverse events on liver function.
The present study was aimed at testing these hypotheses. 
Patients and Methods

SELECTION OF PATIENTS
Safety Considerations
Given that exercise can be associated with acute increases in portal pressure, (10) all included patients with gastroesophageal varices had to be on proper, stable primary or secondary prophylaxis of variceal bleeding. An electrocardiogram was obtained in all patients on the screening visit.
Any of the following was considered exclusion criteria: previous or ongoing ascites; previous or ongoing jaundice, severe bacterial infections leading to hospitalization, portosystemic encephalopathy, hepatocellular carcinoma (HCC); active alcohol consumption (minimum abstinence, 6 months); untreated large gastroesophageal varices; complete portal vein thrombosis; Child-Pugh score >8; transjugular intrahepatic portosystemic shunt; previous liver transplantation; ischemic heart disease or electrocardiographic signs of ischemic heart disease; and severe orthopedic problems limiting the possibility to exercise.
ETHICAL ASPECTS
This study, coordinated by the Hospital Clinic in Barcelona, was approved by the ethics committee of each participating center. The nature of the study was explained to the patients, and a written informed consent was obtained in each case, according to the principles of the Declaration of Helsinki (revision of Edinburgh 2000).
ENDPOINTS
The main endpoints of this study were the changes in BW and in hepatic venous pressure gradient (HVPG) after 16 weeks of intensive LS intervention.
Secondary endpoints included safety (liver-related events and changes in liver function tests) and changes in body composition, oxygen consumption, adipokines, and health-related quality of life after 16 weeks of LS intervention.
VARIABLES OF THE STUDY
All the variables object of the study were assessed on inclusion and after completing 16 weeks of LS intervention.
A diagram illustrating the study design is provided in Supporting Fig. S1 .
Clinical and Laboratory Data
Clinical history data included etiology of liver disease, presence of esophageal varices, and ongoing treatment with nonselective beta-blockers, presence of diabetes, arterial hypertension, and dyslipemia, and concomitant medication; hemodynamic assessment included simple data on systemic hemodynamics: heart rate, systolic, diastolic and mean pressure (evaluated by standard sphygmomanometry after 10-minute rest on the day of the visit); laboratory data included standard tests (hemoglobin, leucocytes count, platelet count, aspartate aminotransferase [AST]/alanine aminotransferase [ALT], gamma-glutamyl transpeptidase, alkaline phosphatase, creatinine, bilirubin, albumin, glucose, sodium, and potassium). Plasma and serum samples were obtained and stored for adipokines, adipocytokines, and cytokines testing. Interleukin (IL)-6; IL-8, IL-1b, insulin, leptin, hepatocyte growth factor (HGF), tumor necrosis factor alpha (TNFa), nerve growth factor (NGF), and monocyte chemoattractant protein 1 (MCP-1) were simultaneously measured on these samples by immunoessay (see Supporting Methods).
HVPG was measured according to the international recommendations as described (see Supporting Methods). (11) Indocianine green clearance, extraction index, and hepatic blood flow were measured in a subgroup of 23 patients, included in two of the participating centers, as described. (12) (see Supporting Methods). Nutritional status assessment was made analyzing the dietary habits of the patients; anthropometric measurement included weight, height, waist circumference, and fat mass (bioelectrical impedance analysis [BIA]; see Supporting Methods).
Physical Activity Assessment
Patients were asked specific questions regarding whether they performed exercise, and in the case that they did regarding its kind, intensity, and duration; specific questions regarded sedentarism (number of hours spent watching television or computer). A subgroup of patients (n 5 24, all included in Barcelona) underwent assessment of maximal oxygen uptake (VO 2 max) by a standard Bruce's test based on progressive effort on a treadmill at baseline and 16 weeks. An indirect estimation of maximal oxygen uptake was used in patients in whom Bruce's test was not available. (13) Quality of Life A liver-disease-specific validated questionnaire was used (chronic liver disease questionnaire, Spanish edition). (14) Patients filled in autonomously the questionnaire, which contains questions regarding six domains of quality of life (abdominal symptoms, fatigue, systemic symptoms, activity, emotional function, and worry). Score for every question is an entire number between 0 (the worst possible) and 7 (the best possible).
LS INTERVENTION
An intensive LS intervention was initiated within 1 week of the baseline HVPG measurement. It consisted of 16 weeks of caloric restriction (diet) and exercise, which are detailed below (see also the Supporting Methods).
Diet
Diet consisted of a tailored reduction in caloric intake of 500-1,000 kCal/day. Protein intake was maintained between 20% and 25% of the total intake in order to reduce the risk of muscle mass loss, but within 0.8 g/kg of ideal BW (calculated for a BMI 5 25 kg/m 2 ) per day. Diet was balanced in order to be not ketogenic and as varied as possible. Carbohydrates accounted for 45%-50% of total kCal; fat content was maintained <35% of total kCal, and 20 g of alimentary fiber was also recommended. No alcohol was allowed.
Physical Activity
On the same week as nutritional intervention initiation, patients began exercising. Exercise was supervised by two professional trainers, one for patients included in Barcelona and one for patients included in Madrid. One weekly 60-minute session of moderate exercise in small groups (1-5 patients) was conducted. Every session consisted in 10 minutes of warmup, 40 minutes of aerobic and strength exercising routine, and 10 minutes of cooling down. Exercise routine was chosen by the trainers, avoiding abdominal workouts/pump, and tailored to a perceived exertion of 4-5/10 (Visual Analogue Scale) or 10-12 Borg Rating of Perceived Exertion Scale. In addition, all patients were instructed to increase their daily standard physical activity. The total amount of physical activity over the 16 weeks of the study was estimated by calculating the metabolic equivalents of tasks (METs). (15) Clinical Follow-up Once a month, the patient was seen by one of the participating hepatologists in order to assess changes in the clinical status and record any relevant event and changes of medication occurring during the study. An extra visit was scheduled 6 months after the completion of the 16-week lifestyle intervention in order to evaluate medium-term safety and BW.
SAMPLE SIZE
According to previous data in patients with cirrhosis, changes in HVPG were predefined as clinically relevant if 10%. (16) Changes in BW were predefined as clinically relevant if 5%. (17) Based on data obtained in patients without cirrhosis with obesity, (18) we assumed that a maximum of 50% of the included patients would be able to decrease BW to this extent. Because no data regarding changes in HVPG associated with BW changes were available previous to this study, we hypothesized that 30% of patients showing a clinically relevant weight loss would also show a clinically relevant reduction in HVPG. With these assumptions, accepting an alpha error of 0.05, a beta error of 0.20, and 10% subject loss during the study, using Fisher's exact test, the inclusion of 60 patients was required to demonstrate the existence of a clinical association between weight loss and reduction in HVPG.
STATISTICAL ANALYSIS
A minimum attendance of 30% to the LS intervention visits was required to enter the final analysis. Quantitative variables are expressed as mean and SD, whereas qualitative variables are expressed as absolute and relative frequencies. Comparisons between groups were made by the Student t test, Mann-Whitney U test, or Kruskal-Wallis test, as appropriate for quantitative variables, and by chi-square or Fisher's test for the qualitative variables. Within each group, continuous variables were compared using the Student t test for paired data. Correlations between variables were computed using the Pearson or Spearman Rho coefficient, when appropriate. Statistical analysis was performed with the SPSS 22.0 package (SPSS, Inc., Chicago, IL). The a value was set at 0.05. All P values are two-sided.
All authors had access to the study data and reviewed and approved the final manuscript.
Results
Sixty patients were considered eligible and signed the informed consent; 3 of them were not put on the LS intervention program because of HVPG <6 mm Hg (inclusion error). Among the 57 patients who initiated the program, 7 either did not complete it (withdrawal of consent, n 5 2; suspicion/identification of HCC on ultrasound during the study, n 5 2) or did not fulfil the minimal predefined attendance criteria (n 5 3).
Fifty patients successfully completed the study and were included in the final analysis. Their main characteristics are summarized in Table 1 . The attendance to physical activity sessions and nutritional therapy   FIG. 1 . Effects of the intensive LS intervention on BW in the study population. As shown, a significant decrease was achieved, and 52% of patients showed a BW decrease 5% (a priori defined as "clinically relevant"). Abbreviation: wk, week. session was high, respectively, 88% and 84%. Adherence to calory intake was 75 6 14%. As for nonsupervised physical activity, 39 of 50 patients correctly completed the physical activity log over 16 weeks. Among them, 16 engaged in weekly or biweekly exercising in addition to walking, whereas for 23 walking was the only additional exercise. Overall, the median cumulative walking/exercising time was 123.7 hours (range, 43-241) and the calculated METs were 400.5 (150.5-1,032.9; Supporting Table S1 ).
EFFECT OF INTENSIVE LS INTERVENTION ON BW AND BODY COMPOSITION
The intensive LS intervention induced a significant decrease in BW ( Fig. 1 and Supporting Fig. S2 ), which was, on average, -5.0 6 4.0 kg (P < 0.0001); the decrease was 5% (clinically relevant) in 52% of the included population; in 16%, weight loss was 10%. Changes in BW were similar in the different etiologies of cirrhosis: viral: -6.7 6 3.8 kg (P < 0.0001 vs. baseline); alcohol: -5.5 6 4.8 kg (P < 0.0001 vs. baseline); nonalcoholic steatohepatitis (NASH): 24.1 6 4.0 kg (p 5 0.002 vs. baseline; Kruskal-Wallis test among etiologies, P 5 0.587).
Weight loss was associated with a significant decrease in fat mass, whereas lean mass did not change (Table 2) . BW loss was maintained after 6 months of follow-up (86.2 6 13.7 kg at 16 weeks vs. 85.6 6 13.7 kg after 6 months; P 5 0.257). At this time point, around half of the population referred to have continued on diet (57%) and exercise (53%) after completing the 16 weeks of intensive LS intervention.
EFFECT OF LS INTERVENTION ON HVPG
HVPG significantly decreased after 16 weeks of LS intervention ( Fig. 2 and Supporting Fig. S3 ), from 13.9 6 5.6 to 12.3 6 5.2 mm Hg (P < 0.0001). A clinically relevant decrease in HVPG (namely, 10% vs. baseline) was observed in 42% of the included population; in 24%, HVPG decreased 20%. Furthermore, 4 patients with HVPG 10 mm Hg on inclusion showed a HVPG value <10 mm Hg after 16 weeks of LS intervention.
In the subset of 23 patients that had measurements of hepatic blood flow, similarly to what was observed in the whole included population, there was a significant decrease in HVPG (15.7 6 5.4 mm Hg at baseline vs. 13.7 6 5.1 mm Hg at 16 weeks; P 5 0.015), which was not associated with any change in hepatic blood flow (898 6 520 mL/min at baseline vs. 782 6 382 at 16 weeks; P 5 0.565), but which was associated with a significant improvement in indocyanine green extraction (from 0.54 6 0.17 to 0.59 6 0.19; P 5 0.048). These findings suggest that a decrease in FIG. 2 . Effects of the intensive LS intervention on HVPG in the study population. As shown, a significant decrease was achieved, and 42% of patients showed a HVPG decrease 10% (a priori defined as "clinically relevant"). Abbreviation: wk, week. intrahepatic vascular resistance contributed to the decrease in portal pressure. Figure 3 summarizes the observed changes in HVPG according to the observed reduction in BW. Overall, there was no statistical correlation between changes in BW and HVPG (R 5 0.010; P 5 0.944). However, patients achieving a greater reduction in BW, namely, 10%, exhibited a greater decrease in HVPG (-23.7 6 19.9% vs. -8.2 6 16.6% decrease in HVPG in those reducing BW less than 10%; P 5 0.024). Interestingly, the 4 patients showing a reduction in HVPG below the threshold of 10 mm Hg had decreased their BW 10%.
RELATION OF CHANGES IN BW AND IN HVPG
RELATION OF CHANGES IN HVPG AND CUMULATIVE PHYSICAL ACTIVITY DURING THE STUDY PERIOD
This point was addressed in the 39 patients who provided data regarding the amount of nonsupervised physical activity they carried out over the study period. A more-intense physical activity, namely, above the median of the study group (METs, 400.5 over 16 weeks; Supporting Table S1), was associated with a more-marked decrease in HVPG (-16.7 6 17.3% in patients above the METs median vs. -5.1 6 19.9 in patients exercising below the METs median; P 5 0.054). The beneficial effect of exercise resulted statistically significant only in patients showing nonclinically relevant changes in BW (Table 3) . These results suggest a possible independent effect of BW reduction and physical activity on portal pressure.
RELATION OF CHANGES IN HVPG AND BW WITH OTHER VARIABLES
The presence of diabetes and a higher fat mass on BIA were associated, respectively, to lack of clinically relevant reduction of BW and HVPG after the intensive LS intervention (Table 1) . Patients with diabetes showed a lower change in HVPG as compared to nondiabetic patients (% change in HVPG, -5.2 6 16.7% vs. -14.7 6 17.9%; P 5 0.06).
HVPG and body weight decreased similarly in patients on nonselective beta-blockers (NSBBs) versus those not taking NSBBs (Table 1) . The adherence to diet of patients on NSBBs was similar to that of those not on NSBB (median, 73.1% vs. 81.2%; not significant [NS]), and the median hours spent walking/exercising over 16 weeks was similar as well (122 6 43 vs. 122 6 53 hours; NS). No differences were noted in the improvement of indirectly assessed maximal aerobic capacity of patients on NSBB (from baseline 28.5 6 5.3 to 31.7 6 5.6 mL/ kg/min after LS intervention; P < 0.0001) and not on NSBB (from baseline 28.3 6 5.6 to 30.9 6 6.1 mL/kg/ min after LS intervention; P < 0.0001).
Having experienced or not an episode of variceal bleeding, cirrhosis etiology, severity of portal hypertension, presence/absence of arterial hypertension, or dyslipidemia did not influence these results. Among the baseline variables, on a multivariate analysis including fat mass and diabetes, only fat mass remained negatively and independently associated with HVPG response to LS intervention (beta coefficient, -0.129; P 5 0.030).
CHANGES IN INSULIN, ADIPOKINES/ADIPOCYTOKINES, AND CYTOKINES
Most of the tested plasma levels of cytokines, namely, IL-1, IL-6, IL-8, HGF, NGF, TNFa, and MCP-1, did not change after the LS intervention. Serum insulin and leptin significantly decreased after LS intervention (Table 2) , their decrease being greater in patients showing a clinically relevant weight loss. Insulin decreased by 33 6 30% in patients with weight loss 5% versus 5 6 55% in those with weight loss <5% (P 5 0.043). As a consequence, homeostasis model assessment (HOMA) decreased from 9.5 6 9.4 to 6.1 6 4.8 (P 5 0.015), and quantitative insulin sensitivity check index (QUICKI) increased from 0.29 6 0.03 to 0.31 6 0.04 (P 5 0.008). Similarly, leptin decreased by 42 6 25% in patients with weight loss 5% versus 4 6 43% in those with weight loss <5% (P 5 0.001). Nevertheless, changes in cytokines were similar in patients who showed a clinically relevant HVPG decrease versus those who did not.
CHANGES IN QUALITY OF LIFE
Quality of life significantly improved after LS intervention (global score, 5.5 6 1.0 vs. 5.2 6 1.0 at baseline; P < 0.001). A significant improvement was noticed in all the domains of the questionnaire (Supporting Fig. S4) ; the improvement was particularly evident in patients achieving a clinically relevant weight loss (global score, 5.7 6 1.0 vs. 5.3 6 1.1 at baseline; P < 0.0001; all domains).
SAFETY
None of the patients experienced episodes of clinical decompensation during the 16 weeks of lifestyle intervention. Child-Pugh and Model for End-Stage Liver Disease (MELD) scores did not change after 16 weeks of diet and exercise (Table 2) . Adverse events during the 16 weeks of LS intervention were few: 1 case of mild pretibial edema, spontaneously disappeared; 1 reported worsening of asthma requiring increase in bronchodilators dosage; and 1 episode of arthritis attributed to gout. On the other hand, 4 patients (1 on insulin alone, 2 on insulin1metformin, and 1 on metformin alone) required reduction in their medication for diabetes and 1 patient stopped spironolactone for disappearance of lower-limb edema.
Discussion
Obesity incidence is increasing dramatically worldwide and is currently common in patients with compensated cirrhosis.
(1,2) It has been previously shown that obesity has a negative impact on the natural history of cirrhosis, (1, 2) but very little is known about how these two chronic conditions interact. More specifically, it is unknown whether standard measures correcting obesity, that have a positive effect on many of its metabolic and cardiovascular consequences, (19) can also improve the course of cirrhosis through improving portal hypertension.
The major finding of this study is that a short (4 months) intensive LS changes intervention, consisting of tailored diet and supervised exercise of moderate intensity, is able to reduce portal pressure in patients with cirrhosis and overweight or obesity. Importantly, the LS intervention proved safe, given that no episode of clinical decompensation was observed during the study, and liver function tests remained unchanged.
Over 40% of the included patients showed a clinically relevant benefit on portal pressure, defined as a decrease in HVPG 10% of baseline. Such a decrease has been shown to be of clinical relevance preventing ascites in patients on primary prophylaxis with NSBB (16) and was associated with a decreased formation of varices in compensated portal hypertensive patients without esophageal varices. (20) Furthermore, the decrease in HVPG was 20% of baseline in one quarter of the included patients, a magnitude of reduction that has been associated with a decrease in the incidence of all complications of portal hypertension and with improved survival when achieved using chronic NSBBs. (21) (22) (23) The amount of weight loss showed no linear relationship with the degree of HVPG reduction, suggesting that the mechanisms leading to the reduction in portal pressure are likely complex and may differ among patients; however, patients achieving a greater weight loss, namely, >10% of BW, also showed a significantly greater HVPG reduction, including more frequently achieving a >10% decrease in HVPG and reaching a final HVPG below 10 mm Hg (the risk threshold for developing complications from portal hypertension). These results might justify recommending a weight loss of at least 10% in this population, in order to maximize the likelihood of a clinically relevant benefit on portal pressure. As for the possibility of predicting which patients would benefit more from a lifestyle intervention, we observed no significant influence of etiology, severity of portal hypertension, presence/absence of previous episodes of variceal bleeding, and presence/absence of arterial hypertension or dyslipidemia; however, the presence of diabetes was associated with a lower reduction in BW and in HVPG, suggesting that, in this population, other approaches should be attempted. Interestingly, a higher fat mass on inclusion was associated with lack of clinically relevant reduction of HVPG after the intensive LS intervention. This finding is intriguing and points to the possibility that adipose tissue mass, rather than BMI, is important in the modulation of portal hypertension. However, it has been previously shown that the study of body composition by BIA has limitations in patients with cirrhosis, mostly attributed to erratic measurements in case of water retention. (24) Given that our population excluded patients with previous or ongoing ascites, it is unlikely that water retention could have prevented a correct evaluation of the effect of BMI and its changes on portal pressure.
Patients on NSBBs showed an attendance to exercising and an improvement in maximal aerobic capacity similar to that of patients not on NSBBs, consistent with results obtained in subjects without cirrhosis showing that NSBBs do not prevent a traininginduced amelioration of VO 2 . (25) Notably, the positive effect of diet and exercise on HVPG was observed also in patients already on NSBBs, confirming that this nonpharmacological approach leads to an added benefit in cirrhosis. This finding further suggests that the mechanism of the reduction in HVPG achieved through the LS intervention differs from that of NSBBs (splanchnic vasoconstriction).
(3) Indeed, it is worth noting that in the subgroup of our patients that had measurements of hepatic blood flow before and after LS intervention, no significant change was observed; a decrease in HVPG in the context of lack of changes in liver blood flow is another strong argument indicating a decrease in hepatic vascular resistance. Also, as discussed below, the positive effect of weight loss on insulin resistance and leptin release probably resulted in a fall in hepatic resistance and, in this way, mediated the decrease in HVPG observed after weight loss. (8, 26) It should be emphasized that our study included only patients without ascites and without any previous episodes of ascites; this was done to ensure homogeneity of the population and to avoid the potential detrimental effect of weight loss in patients that are almost invariably sarcopenic. (9) On the other hand, it is important to observe that in the present study, weight loss was not associated with a reduction in lean mass (mostly muscle mass), likely attributed to the protective effect of exercise on muscle mass (27) and of the adequate protein intake provided by the tailored diet. While further studies are needed, our results suggest that in order to avoid worsening or onset of sarcopenia in obese patients with cirrhosis in whom BW reduction is attempted, exercise needs to be combined with calorie restriction, and diet macronutrients should include an appropriate amount of protein.
Given the pragmatic design of the study that included both tailored diet and exercise, we did answer the question of whether the observed effect on HVPG was attributed to only one of them, and regarding the specific role of each of the two components of LS intervention. According to data obtained in patients with NAFLD/NASH, the combination of diet and exercise is more effective in achieving a significant weight loss, but exercise per se seems sufficient to reduce the amount of visceral fat. (27) Nevertheless, in a subgroup of our study population, we observed that a higher number of hours spent exercising during the study period was associated with a more pronounced decrease in HVPG, and that exercise may possibly explain HVPG reduction in some patients not achieving a clinically relevant weight loss ( Fig. 3; Table 3 ). Even if preliminary, our data suggest that physical activity per se might modulate portal pressure in cirrhosis.
The present study has some limitations; some of them are inherent to any exploratory pilot study, without randomized allocation to intervention or to a control group. Nonetheless, the likelihood that the HVPG spontaneously decreased in the included patients is very low, as proved by several studies addressing hemodynamic changes in compensated cirrhosis not undergoing etiological treatment. Of note, this study was conducted before the new generation of direct antiviral agents for hepatitis C was available in Spain. We cannot provide firm data on the molecular mechanisms leading to portal pressure decrease; however, our findings led us to propose that the decrease in insulin and, in particular, of leptin, could mediate changes in portal pressure occurring over a relatively short period attributed to their ability to modulate intrahepatic vascular resistance (Fig. 4) . Insulin (and insulin resistance expressed either as HOMA or QUICKI indices) and leptin overall decreased after the lifestyle intervention and markedly decreased in patients who lost 10% of BW. It is worth noting that we have recently reported that leptin-receptor blockade decreases hepatic vascular resistance and portal pressure in experimental cirrhosis, (8) and that the correction of insulin resistance by metformin has a similar effect. (26) This reinforces the view that reduced leptin levels and improved insulin sensitivity through LS intervention may be part of the mechanisms involved in the decrease in HVPG observed in our patients. On the other hand, it should be noted that the decrease in insulin and leptin levels did not differ between patients showing a 10% decrease in HVPG or not. Therefore, our findings suggest that although metabolic changes are likely to be involved, they cannot fully explain our observations. We cannot provide data on the expression of these cytokines on liver tissue, given that repeat liver biopsies were not performed because of ethical and economical reasons; therefore, the mechanism linking changes in BW to portal hypertension remain an open question for future studies. Pure NASH-related cirrhosis (without other concomitant etiological factors) was present in one fourth of patients included in this study. This small sample size did not allow us providing data regarding a possible (and likely) more-marked effect of LS intervention on portal pressure in this etiology.
Another limitation of the study is that we cannot assess whether the benefit of the LS intervention would be maintained, improved, or lost over a longterm follow-up, given that the observation period was limited to the 4 months of LS intervention plus 6 months of follow-up. It is possible that the beneficial effect hereby reported fades over time in case of new increases in BW and/or a sedentary life; however, it is equally likely that repeated intervention would maintain the beneficial effect. It is worth noting in this regard that the success of the program in terms of achieving a BW loss of >5% exceeded all expectations (mostly derived from the obesity/diabetes field). It is likely that the excellent attendance and adherence to the program was partly attributable to its intensive nature (with 10 nutritionist visits over 4 months and weekly sessions with a personal trainer), but we believe they largely reflect the marked benefits on the perceived quality of life reported by the patients. This is likely to explain why the weight loss persisted unmodified during the 6 months of follow-up. Future studies should address whether new electronic tools, such as electronic fitness trackers (bracelets, watches, or clipons), might help in maintaining good long-term adherence to LS changes.
In conclusion, an intensive 16-week program of tailored diet and moderate exercise can be safely recommended to achieve weight loss and HVPG decrease in overweight/obese patients with compensated cirrhosis and portal hypertension, and can be considered a useful nonpharmacological intervention in this population.
